Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 5 Sarcoma 4 Neoplasms 4 Hematologic Neoplasms 4 Breast Neoplasms 4 Brain Neoplasms 4 Pancreatic Neoplasms 3 Melanoma 3 Glioma 3 Thyroid Cancer, Papillary 2 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Leukemia, Myeloid, Acute 2 Central Nervous System Neoplasms 2 Wilms Tumor 1 Uveal Melanoma 1 Thrombocytosis 1 Solid Tumors 1 Solid Tumor 1 Sarcoma, Ewing 1 Recurrence 1 Rare Tumour 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Noonan Syndrome 6 1

Interventions

Letrozole 6 Radiotherapy 4 Carboplatin 4 atamestane 3 Trastuzumab 3 Toremifene 3 Magnetic Resonance Spectroscopy 3 Fulvestrant 3 Docetaxel 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 Tamoxifen 2 Paclitaxel 2 Gene Expression Profiling 2 Estrogen Receptor Modulators 2 Capecitabine 2 Aromatase Inhibitors 2 Amplified Fragment Length Polymorphism Analysis 2 repotrectinib 1 proto-oncogene protein c-fes-fps 1 palbociclib 1 neratinib 1 gallium 68 PSMA-11 1 fluciclovine F-18 1 entrectinib 1 Zolpidem 1 Vorinostat 1 Vinorelbine 1 Venlafaxine Hydrochloride 1 Thiotepa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Lobular × entrectinib × Clear all

NCT04551495 2024-12-04

ROSALINE

Jules Bordet Institute

Phase 2 Unknown

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡